WALPAR NUTRITIONS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 138 INR | -0.36% |
|
+9.52% | +66.97% |
| 2023 | Walpar Nutritions Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| 2023 | Walpar Nutritions Limited Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| Sales 2022 | 268M 3.21M | Sales 2023 | 354M 4.24M | Capitalization | 229M 2.75M |
|---|---|---|---|---|---|
| Net income 2022 | 3M 35.95K | Net income 2023 | 5M 59.91K | EV / Sales 2022 | 0.71 x |
| Net Debt 2022 | 67.9M 814K | Net Debt 2023 | 97.6M 1.17M | EV / Sales 2023 | 0.92 x |
| P/E ratio 2022 |
29.9
x | P/E ratio 2023 |
38.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.36% | ||
| 1 week | +9.52% | ||
| Current month | +31.12% | ||
| 1 month | +31.12% | ||
| 3 months | -0.65% | ||
| 6 months | +67.07% | ||
| Current year | +66.97% |
1 week
132.30
138.90
1 month
110.00138.90
Current year
78.00153.95
1 year
66.00153.95
3 years
25.50153.95
5 years
25.50153.95
10 years
25.50153.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 47 | 19/21/19 | |
Sejal Ladhawala
DFI | Director of Finance/CFO | 45 | 16/09/16 |
| Director/Board Member | 37 | 29/20/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sejal Ladhawala
DFI | Director of Finance/CFO | 45 | 16/09/16 |
| Chief Executive Officer | 47 | 19/21/19 | |
| Director/Board Member | 33 | 29/20/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 138 | -0.36% | 2,000 |
| 26/24/26 | 138.5 | +4.69% | 8,000 |
| 25/24/25 | 132.3 | +5.00% | 4,000 |
Delayed Quote NSE India S.E., April 29, 2024 at 05:10 pm IST
More quotes
Walpar Nutritions Limited is an India-based vertically integrated herbonutraceutical products manufacturing company. The Company is engaged in manufacturing, marketing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic products online and offline. It also manufactures various private label/third party brands to different companies across the country and overseas as well own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceuticals formulation. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids. Its products include Pcos Care Forte, Procive-F, Procive-M, Proplus, BIOMID, FERROF, FTM-plus, FTW-plus, G-Flora INOSIA-F, Joint-CR, NI-1000, Ortin-5, Ova-Wom, PCOS-CARE, Refitil-F, Refitil-M, Seagut, Spinac, TRIVITA, flaxseed- Oil, Ironica-CR, Magorich, PDF, PIYO, and Ashyuka Plus.
Sector
Other Specialty Retailers
Calendar
24/10/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +66.97% | 7.51M | |
| -.--% | 843M | |
| -1.57% | 652M | |
| +3.25% | 372M | |
| +23.66% | 229M | |
| -.--% | 143M | |
| +110.87% | 58.68M |
- Stock Market
- Equities
- WALPAR Stock
